Inventiva (NASDAQ:IVA) Now Covered by Analysts at UBS Group

UBS Group started coverage on shares of Inventiva (NASDAQ:IVA) in a report published on Tuesday morning, Marketbeat reports. The brokerage issued a neutral rating and a $3.00 price target on the stock.

IVA has been the subject of several other reports. HC Wainwright decreased their price target on shares of Inventiva from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, October 15th. Stifel Nicolaus decreased their price target on shares of Inventiva from $25.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, September 26th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

Inventiva Stock Up 2.3 %

Shares of IVA opened at $2.72 on Tuesday. Inventiva has a twelve month low of $1.53 and a twelve month high of $4.75. The company has a 50 day moving average of $2.33 and a 200-day moving average of $2.67.

Hedge Funds Weigh In On Inventiva

An institutional investor recently bought a new position in Inventiva stock. Virtu Financial LLC purchased a new stake in shares of Inventiva S.A. (NASDAQ:IVA) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 10,490 shares of the company’s stock, valued at approximately $38,000. Institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.